Oncology Clinical Trials Market - Forecast(2021 - 2026)

Report Code: HCR 1377 Report Format: PDF + Excel (Delivery in 48 Hrs)

Oncology Clinical Trials Market Overview

The Oncology Clinical Trials Market size is forecast to reach $16.22 billion by 2025, growing at a CAGR of 7.1% during the forecast period 2020-2025. Increasing the number of cancer cases and rising need for personalized medicines is the major factor driving the growth of the market. Increasing innovation in the field of oncology and supportive government initiatives is set to further enhance the overall market demand for the Oncology Clinical Trials Market during the forecast period 2020-2025.

Oncology Clinical Trials Market Report Coverage

The report: “Oncology Clinical Trials Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Oncology Clinical Trials Market. 
By Phase: Phase 1, Phase 2, Phase 3, and Phase 4
By Cancer Type: Lung Cancer, Breast Cancer, Thyroid Cancer, Leukemia, Liver Cancer, Skin Cancer, Lymphoma, Pancreatic Cancer, Colon & Rectal Cancer, Urinary System Cancer, Astrocytoma, Advanced Malignancies, All Solid Tumors, Chordoma, and Others
By Study Design:  Interventional, Observational, and Expanded Access
By Geography: North America, Europe, Asia Pacific, and Rest of the World (RoW)

Key Takeaways

  • North America dominated the Oncology Clinical Trials Market in 2019 owing to the increasing adoption of new technologies in clinical research and increasing government support. The Oncology Clinical Trials Market scope for different regions will be provided in the final report.
  • The rising need for effective treatment against various types of cancer and scientific advancements in immunology, molecular biology, and genetics is likely to aid in the market growth of the Oncology Clinical Trials Market.
  • Detailed analysis of the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Oncology Clinical Trials Market report.
  • The Absence of scientific knowledge and misuse of statistics & data is poised to create hurdles for the Oncology Clinical Trials Market.

Oncology Clinical Trials Market Segment Analysis - By Phase

Phase 2 held the largest share in the Oncology Clinical Trials Market in 2019 and is estimated to grow at a CAGR of 7.8% during the forecast period 2020-2025. Phase II trials act as screening tools to assess whether a treatment has sufficient activity to warrant further investigation in large costly phase III trials.  Phase II studies must be designed, performed, and reported to allow accurate interpretation of results and to obtain the best quality data to facilitate and inform unbiased decisions regarding the subsequent development of the drug(s) understudy in the phase III setting.  Also, Phase III requires a higher number of patients and often a longer treatment period. Phase 2 is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025.

Oncology Clinical Trials Market Segment Analysis - By Cancer Type 

The Leukemia held the largest share in the Oncology Clinical Trials Market in 2019. Leukemia is a blood cancer caused by a rise in the number of white blood cells in the body. Those white blood cells crowd out the red blood cells and platelets that body needs to be healthy. No one knows exactly what causes leukemia. People who have it have certain unusual chromosomes, but the chromosomes don’t cause leukemia. Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. The kind of breast cancer depends on which cells in the breast turn into cancer. It can spread outside the breast through blood vessels and lymph vessels. When breast cancer spreads to other parts of the body, it is said to have metastasized. Leukemia is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025.

Oncology Clinical Trials Market Segment Analysis - By Geography

North America dominated the Oncology Clinical Trials Market in 2019 with a share of more than 42.13%, followed by the Asia Pacific owing to the increasing adoption of new technologies in clinical research. Increasing government support and increasing research & development in oncology is also increasing the growth of the Oncology Clinical Trials Market in this region.
However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the increasing availability of a large patient pool, technological evolution, and demand for contract research organizations to conduct clinical trials.

Oncology Clinical Trials Market Drivers

Scientific advancements in immunology, molecular biology, and genetics

Scientific advancements in immunology, molecular biology, and genetics are increasing the growth of the Oncology Clinical Trials Market. There have been several major advances in molecular biology focusing on their benefits and limitations when applied to investigating oncology. New technologies either improve existing techniques or develop new approaches to old questions to generate information more quickly. Mutant and chimeric DNA sequences are often useful for analyses of the structure and function of genes and proteins. Mutations can be introduced by using PCR primers that incorporate one or more point mutations, deletions, or insertions. PCR-based methods can be the only option if the amount of starting material is limited (as often occurs when analyzing mRNA expression in primary cells) or if the target sequence is expressed at a very low copy number. Thus, increasing the growth of the Oncology Clinical Trials Market during the forecast period 2020-2025.

Increasing number of cancer cases

An increasing number of cancer cases is increasing the growth of the Oncology Clinical Trials Market. Cigarette smoking is linked to many kinds of cancer, especially lung cancer. Overweight and obesity raise the risk for female breast, colorectal, oesophageal, uterine, pancreas, and kidney cancers. After increasing over the past several decades, about two-thirds of adults and one-third of children are now overweight or obese. Cancers caused by infections are also expected to increase. New cases of liver cancer are expected to go up more than 50%, likely the result of the increase in hepatitis infections. Thus, increasing the growth of the Oncology Clinical Trials Market during the forecast period 2020-2025.

Oncology Clinical Trials Market Challenges

Absence of scientific knowledge and misuse of statistics & data

Some of the factors that are set to impede the growth of the Oncology Clinical Trials Market are the absence of scientific knowledge and the misuse of statistics & data. The success of oncology clinical trials depends on the level of engagement of its participants, oncologists, clinical staff, and patients from the very first phase. Many roadblocks arise within these groups for both logistical and psychological reasons. As a consequence, less than 5% of adult patients diagnosed with cancer enroll in oncology clinical trials owing to trial availability, site access, oncologist’s willingness to propose enrollment, clinical staff commitment, and patient’s concern. Thus, hampering the growth of the Oncology Clinical Trials Market.

Oncology Clinical Trials Market Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Oncology Clinical Trials Market. In 2019, the Oncology Clinical Trials Market share is consolidated by the top ten players present in the market. Oncology Clinical Trials Market, the top 10 companies are PAREXEL International Corporation, PRA Health Sciences, Syneos Health, Medpace, Novotech, and Pivotal among others.

Acquisitions/Product Launches

  • In September 2019, IQVIA announced its collaboration with Cancer Researchers to advance the use of real-world evidence and expand clinical research in oncology. 
  • In June 2018, Acurian and Synexus, a part of PPD, launched SynexusPlus. SynexusPlus is a site solution for patient enrollment in clinical studies. This initiative is anticipated to improve clinical trial productivity.

For more Lifesciences and Healthcare related reports, please click here
1. Oncology Clinical Trials Market  - Overview
    1.1 Definitions and Scope
2. Oncology Clinical Trials Market  - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Phase
    2.3 Key trends by Cancer Type
    2.4 Key trends by Geography
3. Oncology Clinical Trials Market  – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Oncology Clinical Trials Market  - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Oncology Clinical Trials Market  – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Oncology Clinical Trials Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Oncology Clinical Trials Market  – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Oncology Clinical Trials Market – By Phase(Market Size –$Million/$Billion)
    8.1 Phase 1
    8.2 Phase 2
    8.3 Phase 3
    8.4 Phase 4
9. Oncology Clinical Trials Market – By Cancer Type(Market Size –$Million/$Billion)
    9.1 Lung Cancer
    9.2 Breast Cancer
    9.3 Thyroid Cancer
    9.4 Leukemia
    9.5 Liver Cancer
    9.6 Skin Cancer
    9.7 Lymphoma
    9.8 Pancreatic Cancer
    9.9 Colon & Rectal Cancer
    9.10 Urinary System Cancer
    9.11 Astrocytoma
    9.12 Advanced Malignancies
    9.13 All Solid Tumors
    9.14 Chordoma
    9.15 Others
10. Oncology Clinical Trials Market – By Study Design(Market Size –$Million/$Billion)
    10.1 Interventional
    10.2 Observational
    10.3 Expanded Access
11. Oncology Clinical Trials Market  -  By Geography(Market Size –$Million/$Billion) 
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of APAC
    11.4 Rest of the World
        11.4.1 Middle East
        11.4.2 Africa
        11.4.3 South America
12. Oncology Clinical Trials Market  - Entropy
13. Oncology Clinical Trials Market  – Industry/Segment Competition Landscape      Premium  
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Oncology Clinical Trials Market  – Key Company List by Country Premium  Premium
15. Oncology Clinical Trials Market  Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4 
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.